Trial Profile

"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy: SPOTLIGHT

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eptacog alfa (Primary)
Indications Haemorrhage
Focus Therapeutic Use
Acronyms SPOTLIGHT

Most Recent Events

09 Feb 2023 Results of a pre-specified analysis assessing impact of delays from baseline imaging to study drug administration on hematoma expansion published in the Stroke
23 Aug 2019 New trial record
19 Aug 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com